Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: A prospective study

Gynecologic and Obstetric Investigation

Volumn 58, Issue 1, 2004, Pages 42-48

  Tamaoka, Yukoku ^a,b   Orikasa, Hideki ^a   Sumi, Yukari ^a,b   Sakakura, Keiichi ^a,b   Kamei, Kiyoshi ^a,b   Nagatani, Midori ^a   Ezawa, Sachiko ^a,b  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Danazol; Endometrial hyperplasia treatment; Intrauterine device

Indexed keywords

DANAZOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUATION; NECROSIS; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; STROMA;

ADULT; DANAZOL; ENDOMETRIAL HYPERPLASIA; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MENSTRUATION; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; UTERUS;

EID: 4344713481     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077882     Document Type: Article

References (25)

1. Kurman RJ, Kaminski PE, Norris HJ: The behavior of endometrial hyperplasia: A long-term study of untreated hyperplasia in 170 patients. Cancer 1985;56:403-412.
2. Sedati A, Mariani L, Giovinazzi R, Yacoub M, Atlante G: The effectiveness of danazol therapy in menopausal women affected by endometrial hyperplasia. Clin Exp Obstet Gynecol 1992;19:161-165.
3. Schindler A: Conservative treatment modalities of glandular and adenomatous endometrial hyperplasia. Zentralbl Gynäkol 1996;118:359-369.
4. Soh E, Sato K: Clinical effect of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1996;66:983-98.
5. Jassoni VM, La Marca L, Ciotti P, Flamigni C, Naldi S, Bulletti C, Vignudelli A: Preliminary report on postmenopausal endometrial hyperplasia treatment with danazol: Histological and endocrinological aspects. Cancer Detect Prevent 1986;9:331-335.
6. Montemagno U, De Placid G, Colacurci N, Zullo F: Endometrial effects of danazol in perimenopausal abnormal bleeding. Ann NY Acad Sci 1991;622:283-290.
7. Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S: Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: A prospective study. Hum Reprod 1999;14:479-484.
8. Pérez-Medina T, Bajo J, Folgueria G, Haya J, Ortega P: Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: Long-term follow-up. Gynecol Oncol 1999;73:299-304.
9. Crosignani PG, Vercellini P, Mosconi P, Scid B, Oldani S, Cortesi I, Giorgi OD: Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-263.
10. Imperato F, Preniola G, Mossa B, Marziani R, Perniola F, Stragapede B, Napolitano C: The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years). Minerva Ginecol 2002;54:271-278.
11. Zhu P, Liu X, Luo H, Gu Z, Chen J, Xu R, Lian S, Wu S, Wang J: The effect of a levonorgestrelreleasing intrauterine device on human endometrial estrogen and progesterone receptors after one year of use. Hum Reprod 1999;14:970-975.
12. Tamaoka Y, Oosawa Y, Sumi Y, Kamei K, Yokokura T, Sakakura K: New method of treatment of adenomyosis with intrauterine device containing danazol. Acta Obstet Gynecol Scand Suppl 1997;167(suppl 76):67.
13. Igarashi M: A new therapy for pelvic endometriosis and uterine adenomyosis: Local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol 1990;16:1-12.
14. Goss GM: Gray's Anatomy. Philadelphia, Lea & Febiger, 1973, ed 29, pp 715-716.
15. Silverberg SG, Kurman RJ: Tumor of the uterine corpus and gestational trophoblastic disease. Washington, Armed Forces Institute of Pathology, 1992.
16. Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-440.
17. Mariani L, Sedati A, Giovinazzi R, Sindico R, Atlante G: Postmenopausal endometrial hyperplasia: Role of danazol therapy. Int J Gynecol Obstet 1994;44:155-159.
18. Barbieri RL, Lee H, Ryan KJ: Danazol binding to rat androgen, glucocorticoid, progesterone and estrogen receptors: Correlation with biologic activity. Fertil Steril 1979;31:182-185.
19. Kauppila A, Vierrikko P, Isotalo H, Ronnberg L, Vihko R: Cytosol estrogen and progestin receptor concentrations and 17β-hydroxysteroid dehydrogenase activities in the endometrium and endometrial tissue. Acta Obstet Gynecol Scand Suppl 1984;123:45-49.
20. Bergvist A, Ljungberg O, Skoog L: Immunohistochemical analysis of estrogen and progesterone receptors in endometriotic tissue and endometrium. Hum Reprod 1993;8:1915-1922.
21. Lessey B, Metzger DA, Haney AF, MacCarty K: Immunohistochemical analysis of estrogen and progesterone receptor in endometriosis: Comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 1993;51:409-415.
22. Urabe M, Yamamoto T, Kitawaki Jo, Honjo H, Okada H: Estrogen biosynthesis in human uterine adenomyosis. Acta Endocrinol (Copenh) 1989;121:259-264.
23. Yamamoto T, Noguchi T, Tamura T, Kitawaki J, Okada H: Evidence for estrogen synthesis in adenomyotic tissues. Am J Obstet Gynecol 1993;169:734-738.
24. Barbieri L, Canick A, Makris A, Todd R, Davies I, Ryan KJ: Danazol inhibits steroidogenesis. Fertil Steril 1977;28:809-813.
25. Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, Ezawa S: Novel therapy of endometrial hyperplasia with a danazolreleasing intracervical uterine device. XIth World Congress of IFCPC, Barcelona 2002, pp 323-324.